Obesity reduced the anti-cancer effects of the antidiabetic adiponectin receptor agonist AdipoRon in diet-induced obese mice with orthotopic pancreatic cancer through a mechanism involving IGF-1, IGF-1R, and ERK1/2 signaling (5), indicating the importance of weight loss in combating pancreatic cancer in obese patients. This evidence concerns the gene IGF1R and familial pancreatic carcinoma.